Medication info
Januritine Comb SR Tablets 50/500 mg

Januritine Comb SR Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Bright blue, oval-shaped, convex film-coated sustained-release tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201933 · Approved 2022.05.11 · Insurance code 671807590

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of two 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, discontinue this medicine immediately.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist patients with type 2 diabetes in controlling their blood sugar levels. Particularly, since it contains both sitagliptin and metformin, it helps effectively improve blood sugar levels when combined with dietary and exercise therapies. This combination of medications is a significant aid for patients struggling to control blood sugar, positively impacting overall diabetes management.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of two 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is coadministered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, discontinue this medicine immediately.

Precautions

This medication contains two components that assist in controlling blood sugar. Firstly, sitagliptin included in this medication can rarely cause severe allergic reactions, which may include serious symptoms such as skin rashes, swelling of the lips or tongue. Additionally, sitagliptin can cause acute pancreatitis, which leads to inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, or vomiting occur, you should consult a doctor immediately. Secondly, the metformin component can rarely cause lactic acidosis, a serious metabolic complication where lactic acid accumulates excessively in the body, which can be fatal. This medication should be avoided by patients with impaired kidney function, those who have heart or liver issues, or those in a state of dehydration, severe infections, or acute myocardial infarction. It is also safest for pregnant or breastfeeding women to avoid taking this medication. Irregular eating patterns, excessive exercise, or concurrent use with other medications may increase the risk of hypoglycemia or other side effects, necessitating caution. While taking this medication, it is necessary to regularly check kidney function and blood tests to confirm safety, and monitoring vitamin B12 levels periodically is advisable. Alcohol consumption may increase the risk of lactic acidosis, so it should be avoided while on this medication. This medication should be discontinued for a certain period before and after surgery, and if any sudden abdominal pain, breathing difficulties, severe fatigue, or changes in consciousness occurs, notify healthcare personnel immediately. Some patients may experience side effects such as diarrhea, nausea, headache, upper respiratory infections, and when used with other hypoglycemic agents, there may be an increased risk of hypoglycemia, so caution is necessary. Additionally, this medication can interact with certain drugs, so if there are other medications being taken, it is essential to inform a doctor or pharmacist. Lastly, safety and efficacy of this medication have not been established in children under 10 years old or adolescents under 18 years old, and it is not recommended for them.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 19 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • arthralgia with severity and disability
  • blistering dermatitis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture and should be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. This will help preserve the efficacy and safety of the medication over time.

Appearance and packaging

Appearance

Bright blue, oval-shaped, convex film-coated sustained-release tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.